2018 American Transplant Congress
Cardiac Grafts from Insulin Resistant Donors Trigger a Heightened Immune Response via Excessive Induction of Autophagy
Background Heart transplantation remains the treatment of choice for many patients with medically refractory heart failure. The use of organs from patients with insulin resistant…2018 American Transplant Congress
A Pre-Transplant Blood-Based Lipid Signature for Prediction of Antibody-Mediated Rejection in Kidney Transplant Patients
Virginia Commonwealth University, Richmond.
BACKGROUNDThere is a lack of biomarkers for pre-kidney transplant immune risk stratification to avoid over- or under-immunosuppression. Since the circulating lipidome is integrally involved in…2018 American Transplant Congress
Comparison of Bortezomib in Addition to Rituximab Based Treatment of Acute Antibody Mediated Rejection in Kidney Transplantation
Purpose:The optimal treatment strategy of acute antibody mediated rejection (AMR) in renal allograft recipients remains undefined. The aim of our study was to compare the…2018 American Transplant Congress
Impact of De Novo DSA (DnDSA) on Outcomes in HLA-Sensitized (HS) Patients Transplanted after IVIG + Rituximab Desensitization (DES)
Introduction: Highly-HLA sensitized patients (HS) with donor specific antibodies (DSA) at transplant are at risk for Type 1 ABMR. However, the incidence of Type 2…2018 American Transplant Congress
Impact of Bw4 and Bw6 Epitope Mismatch on Clinical Outcomes after Renal Transplantation
HLA class II epitope mismatch has been shown to impact the long-term survival of kidney allografts. HLA-B alleles are traditionally grouped by the Bw4 and…2018 American Transplant Congress
Pre-Emptive Rituximab and Intravenous Immunoglobulin (IVIg) Fail to Prevent Rejection in Kidney Transplant Recipients (KTx) with Donor Specific Antibodies (DSA)
Columbia University, New York, NY.
Introduction:IVIg and Rituximab have been used successfully to improve transplantation rates in sensitized patients. DSA detected by Flow crossmatch (FXM+) or Luminex® at time of…2018 American Transplant Congress
Standard- versus Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Kidney Transplant Recipients
Henry Ford Hospital, Detroit, MI.
Background: Although guidelines recommend valganciclovir (VGC) 900 mg daily for cytomegalovirus (CMV) prophylaxis in solid organ transplant patients, multiple centers have reported clinical success, reduced…2018 American Transplant Congress
Retrospective Study of Cryptococcosis in Kidney Transplant Recipients from a Single Center
Background: The mortality of Cryptococcosis remains unchanged among kidney transplant recipients(KTR) over the past two decades, and the prognosis of Cryptococcosis is yet unpredicted. Hence,…2018 American Transplant Congress
Effect of Everolimus on Body Composition; 1-Year after Kidney Transplantation
【Background】Weight gain, and especially visceral fat gain early after kidney transplantation has a worse outcome for metabolic disorder, graft function, and cardiovascular disease. The mammalian…2018 American Transplant Congress
The Incidence and Outcome of Isolated Distal Deep Vein Thrombosis in Kidney Transplant Recipient
Surgery, The Catholic University of Korea, Seoul, Republic of Korea.
Introduction Isolated distal deep vein thrombosis (IDDVT) in kidney transplantation recipient (KTR) is difficult to make decision because it is not common in Korean and…
- « Previous Page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- …
- 211
- Next Page »